Recent retrospective analyses [4, 18] suggest that some EGFR‐mutant NSCLC patients, particularly those with high PD‐L1 expression, may still benefit, although results remain heterogeneous. This evidence concerns the gene CD274 and non-small cell lung carcinoma.